Skip to main content
Olema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · OLMA ISIN · US68062P1066 US Manufacturing
Open in API
Filings indexed 506 across all filing types
Latest filing 2020-11-20 Director's Dealing
Country US United States of America
Listing US OLMA

About Olema Pharmaceuticals, Inc.

https://olema.com/

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. The company concentrates on endocrine-driven diseases, with a primary emphasis on breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). Palazestrant is under investigation in clinical trials as a potential treatment for patients with ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is advancing a pipeline of drug candidates with the goal of developing improved therapeutic options for cancer patients.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-11-20 English
FORM 3 SUBMISSION
Director's Dealing
2020-11-19 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC. It is a registration statement under the Securities Act of 1933 for securities to be issued under employee benefit plans (stock plans). The document includes details about stock plans, registration fees, indemnification of directors and officers, and incorporation by reference of other filings. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration, not an annual report, audit report, or other financial statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2020-11-19 English
FORM 424B4
Capital/Financing Update Classification · 100% confidence The document is a Form 424B4 prospectus filed pursuant to Rule 424(b)(4) related to an initial public offering (IPO) of common stock by Olema Pharmaceuticals, Inc. It details the offering of 11,000,000 shares, the offering price, underwriting discounts, and proceeds to the company. The document includes sections typical of a prospectus such as risk factors, use of proceeds, dividend policy, capitalization, dilution, selected financial data, management's discussion and analysis, business overview, management, executive compensation, principal stockholders, description of capital stock, underwriting, legal matters, and financial statements. The document is a registration statement/prospectus for a public offering, which is a capital raising event. This fits the category of Capital/Financing Update (CAP) as it provides detailed information about the company's capital raising through an IPO. It is not an annual report, earnings release, or other report type. The document length is substantial and contains detailed offering information, not just an announcement or notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is Capital/Financing Update (CAP).
2020-11-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-11-19 English
Regulatory Filings 2020
Regulatory Filings
2020-11-19 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.